Imprecise information on significance of gene variants diminishes value of genetic panel testing
the ONA take:
Advances in technology provide people with the option of undergoing multigene testing, or panel testing, to determine their risk for developing various cancers.
However, an international consortium of authors caution clinicians about using these tests. Although the tests are helpful in identifying genetic mutations with the potential to increase a woman’s risk for breast and other cancers, clinicians need to be aware of, and share with patients, the limitations of test results.
Panel testing covers more than 100 genes, 21 of which are associated with breast cancer. Information about many genetic variants is lacking, and positive results may cause undue stress and anxiety over benign conditions.
In addition, patients may take significant or unnecessary risk-reducing interventions or screenings based on limited information.
The authors acknowledge that there is a significant body of evidence to support clinical action when some genetic variants are identified, such as BRCA1 and BRCA2 gene mutations; however, the implications of many other mutations are too imprecise and require further investigation.
They recommend that patients should be informed of the potential for uncertainty regarding the results.
Advances in technology provide people with the option of undergoing multigene testing determine their risk for developing cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|